Tislelizumab NSCLC Inclusion Recommended for Du...

By HEOR Staff Writer

February 9, 2026

Tislelizumab NSCLC Inclusion in Dutch Basic Package Zorginstituut Nederland's Tislelizumab NSCLC Inclusion Recommendation Zorginstituut Nederland's advis...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications